RU2011124917A - Новая форма введения остеогенных белковых комплексов - Google Patents
Новая форма введения остеогенных белковых комплексов Download PDFInfo
- Publication number
- RU2011124917A RU2011124917A RU2011124917/15A RU2011124917A RU2011124917A RU 2011124917 A RU2011124917 A RU 2011124917A RU 2011124917/15 A RU2011124917/15 A RU 2011124917/15A RU 2011124917 A RU2011124917 A RU 2011124917A RU 2011124917 A RU2011124917 A RU 2011124917A
- Authority
- RU
- Russia
- Prior art keywords
- group
- polysaccharide
- precipitate
- anionic
- acid
- Prior art date
Links
- 230000002188 osteogenic effect Effects 0.000 title claims abstract 11
- 102000007474 Multiprotein Complexes Human genes 0.000 title 1
- 108010085220 Multiprotein Complexes Proteins 0.000 title 1
- 239000002244 precipitate Substances 0.000 claims abstract 20
- 229920001282 polysaccharide Polymers 0.000 claims abstract 17
- 239000005017 polysaccharide Substances 0.000 claims abstract 17
- 125000000524 functional group Chemical group 0.000 claims abstract 16
- 229920001586 anionic polysaccharide Polymers 0.000 claims abstract 15
- 150000004836 anionic polysaccharides Chemical class 0.000 claims abstract 15
- 150000004804 polysaccharides Chemical class 0.000 claims abstract 15
- -1 anionic ions Chemical class 0.000 claims abstract 13
- 230000002491 angiogenic effect Effects 0.000 claims abstract 10
- 230000001889 chemoattractive effect Effects 0.000 claims abstract 10
- 239000003102 growth factor Substances 0.000 claims abstract 10
- 159000000007 calcium salts Chemical class 0.000 claims abstract 9
- 239000000203 mixture Substances 0.000 claims abstract 9
- 102000004169 proteins and genes Human genes 0.000 claims abstract 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 7
- 230000002209 hydrophobic effect Effects 0.000 claims abstract 7
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 150000001408 amides Chemical group 0.000 claims abstract 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims abstract 4
- 150000001450 anions Chemical class 0.000 claims abstract 4
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 4
- 150000002148 esters Chemical class 0.000 claims abstract 4
- 125000005842 heteroatom Chemical group 0.000 claims abstract 4
- 150000007970 thio esters Chemical class 0.000 claims abstract 4
- 230000002378 acidificating effect Effects 0.000 claims abstract 3
- 239000004135 Bone phosphate Substances 0.000 claims abstract 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910019142 PO4 Inorganic materials 0.000 claims abstract 2
- 150000001298 alcohols Chemical class 0.000 claims abstract 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims abstract 2
- 125000002091 cationic group Chemical group 0.000 claims abstract 2
- 150000004679 hydroxides Chemical class 0.000 claims abstract 2
- 235000021317 phosphate Nutrition 0.000 claims abstract 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims abstract 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 4
- 229910052783 alkali metal Inorganic materials 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 150000001768 cations Chemical class 0.000 claims 4
- 230000007935 neutral effect Effects 0.000 claims 4
- 150000001720 carbohydrates Chemical group 0.000 claims 3
- 150000007942 carboxylates Chemical class 0.000 claims 3
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims 2
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 claims 2
- 101710204282 Growth/differentiation factor 5 Proteins 0.000 claims 2
- 101100175316 Mus musculus Gdf5 gene Proteins 0.000 claims 2
- 150000001340 alkali metals Chemical class 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 229920006318 anionic polymer Polymers 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 150000003568 thioethers Chemical class 0.000 claims 2
- UDQCRUSSQAXPJY-VIFPVBQESA-N (2s)-2-amino-3-(1h-indol-3-yl)propan-1-ol Chemical compound C1=CC=C2C(C[C@@H](CO)N)=CNC2=C1 UDQCRUSSQAXPJY-VIFPVBQESA-N 0.000 claims 1
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 claims 1
- WRAUXDQDRDJTKM-UHFFFAOYSA-N 2-(1h-indol-2-yl)ethanamine Chemical compound C1=CC=C2NC(CCN)=CC2=C1 WRAUXDQDRDJTKM-UHFFFAOYSA-N 0.000 claims 1
- 150000008574 D-amino acids Chemical group 0.000 claims 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical class C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- JLSKPBDKNIXMBS-VIFPVBQESA-N L-tryptophanamide Chemical compound C1=CC=C2C(C[C@H](N)C(N)=O)=CNC2=C1 JLSKPBDKNIXMBS-VIFPVBQESA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 238000000975 co-precipitation Methods 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 125000003563 glycoside group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11614408P | 2008-11-19 | 2008-11-19 | |
| US61/116,144 | 2008-11-19 | ||
| US21393909P | 2009-07-31 | 2009-07-31 | |
| FR0903803A FR2948573B1 (fr) | 2009-07-31 | 2009-07-31 | Nouvelle forme d'administration de complexes de proteines osteogeniques |
| FR0903803 | 2009-07-31 | ||
| US61/213,939 | 2009-07-31 | ||
| PCT/FR2009/001332 WO2010058106A1 (fr) | 2008-11-19 | 2009-11-19 | Nouvelle forme d'administration de complexes de protéines ostéogéniques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011124917A true RU2011124917A (ru) | 2012-12-27 |
Family
ID=41719051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011124917/15A RU2011124917A (ru) | 2008-11-19 | 2009-11-19 | Новая форма введения остеогенных белковых комплексов |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8546356B2 (https=) |
| EP (1) | EP2376063A1 (https=) |
| JP (1) | JP2012509303A (https=) |
| KR (1) | KR20110086752A (https=) |
| CN (1) | CN102281868A (https=) |
| AU (1) | AU2009317083A1 (https=) |
| BR (1) | BRPI0916110A2 (https=) |
| CA (1) | CA2744150A1 (https=) |
| FR (1) | FR2948573B1 (https=) |
| IL (1) | IL213001A0 (https=) |
| MX (1) | MX2011005275A (https=) |
| RU (1) | RU2011124917A (https=) |
| SG (1) | SG171388A1 (https=) |
| WO (1) | WO2010058106A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150079145A1 (en) * | 2006-12-14 | 2015-03-19 | DePuy Synthes Products, LLC | Protein stabilization formulations |
| FR2948573B1 (fr) | 2009-07-31 | 2011-11-18 | Adocia | Nouvelle forme d'administration de complexes de proteines osteogeniques |
| FR2943538B1 (fr) * | 2009-03-27 | 2011-05-20 | Adocia | Formulation a action rapide d'insuline recombinante humaine |
| FR2980796B1 (fr) * | 2011-09-30 | 2014-07-04 | Adocia | Oligosaccharides fonctionnalises |
| US9018190B2 (en) | 2009-03-27 | 2015-04-28 | Adocia | Functionalized oligosaccharides |
| FR2956116A1 (fr) * | 2010-02-09 | 2011-08-12 | Adocia | Complexes polysaccharide/bmp-7 solubles a ph physiologique |
| WO2011098962A2 (fr) * | 2010-02-09 | 2011-08-18 | Adocia | Polysaccharides anioniques fonctionnalisés par au moins deux groupements hydrophobes portés par un spacer au moins trivalent |
| FR2958647B1 (fr) * | 2010-04-08 | 2013-08-23 | Adocia | Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive hydrophobe porte par un spacer au moins trivalent. |
| JPWO2012029148A1 (ja) * | 2010-09-01 | 2013-10-28 | 株式会社オステオファーマ | 組換えヒト骨形成タンパク質−２凍結乾燥製剤 |
| WO2012153070A1 (fr) * | 2011-05-10 | 2012-11-15 | Adocia | Oligosaccharides fonctionnalisés |
| JP5950477B2 (ja) * | 2011-08-10 | 2016-07-13 | アドシア | 少なくとも１種の基礎インスリンの注射溶液 |
| US20130231281A1 (en) | 2011-11-02 | 2013-09-05 | Adocia | Rapid acting insulin formulation comprising an oligosaccharide |
| EP2919804B1 (fr) | 2012-11-13 | 2018-01-31 | Adocia | Formulation à action rapide d'insuline comprenant un composé anionique substitué |
| US8945872B2 (en) | 2013-01-25 | 2015-02-03 | Warsaw Orthopedic, Inc. | Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein |
| US9359417B2 (en) | 2013-01-25 | 2016-06-07 | Warsaw Orthopedic, Inc. | Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US9051389B2 (en) | 2013-01-25 | 2015-06-09 | Warsaw Orthopedic, Inc. | Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5) |
| US9169308B2 (en) | 2013-01-25 | 2015-10-27 | Warsaw Orthopedic, Inc. | Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies |
| US8956829B2 (en) | 2013-01-25 | 2015-02-17 | Warsaw Orthopedic, Inc. | Human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| KR102016745B1 (ko) * | 2013-02-01 | 2019-09-02 | 아이진 주식회사 | Ｂｍｐ―７ 및 부형제를 포함하는 흉터 형성의 감소 또는 억제용 조성물 |
| CN103919733A (zh) * | 2014-04-11 | 2014-07-16 | 聂和民 | 一种包裹双生长因子的核壳结构微球及其用途 |
| US9795678B2 (en) | 2014-05-14 | 2017-10-24 | Adocia | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound |
| FR3020947B1 (fr) | 2014-05-14 | 2018-08-31 | Adocia | Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations |
| EP3190089A4 (en) * | 2014-09-01 | 2018-06-20 | Kyushu University, National University Corporation | Method for manufacturing product inorganic compound and product inorganic compound |
| FR3025428A1 (fr) | 2014-09-08 | 2016-03-11 | Adocia | Composition pharmaceutique stable comprenant du pdgf |
| EP3040118A1 (en) * | 2014-12-29 | 2016-07-06 | Galderma S.A. | Ether cross-linked chondroitin hydrogels and their use for soft tissue applications |
| FR3043557B1 (fr) | 2015-11-16 | 2019-05-31 | Adocia | Composition a action rapide d'insuline comprenant un citrate substitue |
| US20190070299A1 (en) * | 2016-02-23 | 2019-03-07 | Matripharm International Inc. | Dual-rate release formulation with high drug loading |
| CN107596451B (zh) * | 2017-08-22 | 2020-11-20 | 东南大学 | 一种基于HA/CS/P(MVE-alt-MA)复合骨修复材料及其制备方法 |
| CN113069591A (zh) * | 2021-03-29 | 2021-07-06 | 黄河三角洲京博化工研究院有限公司 | 一种壳聚糖-聚谷氨酸钙生物敷料及其制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US563461A (en) | 1896-07-07 | Water elevator and carrier | ||
| FR702316A (fr) | 1929-10-04 | 1931-04-04 | Bosch Robert | Cercle de commande destiné à être fixé sur le volant de direction de voitures |
| FR805506A (fr) | 1936-04-27 | 1936-11-21 | Est Aciers Fins | Procédé de fabrication d'aciers fins |
| FR854621A (fr) | 1938-09-29 | 1940-04-19 | Perfectionnements aux procédés de construction et aux briques employées avec ces procédés | |
| US2387201A (en) | 1942-01-12 | 1945-10-16 | Bonneville Ltd | Mono-acyl ethylene diamines |
| US4455256A (en) * | 1981-05-05 | 1984-06-19 | The Regents Of The University Of California | Bone morphogenetic protein |
| EP0160103B1 (en) | 1983-10-26 | 1990-06-20 | Kanebo, Ltd. | Proteinous emulsifier, process for its preparation, and emulsified cosmetic preparation containing same |
| US5676976A (en) | 1995-05-19 | 1997-10-14 | Etex Corporation | Synthesis of reactive amorphous calcium phosphates |
| US6656922B2 (en) | 1998-05-28 | 2003-12-02 | Mediplex Corporation, Korea | Oral delivery of macromolecules |
| FR2794649B1 (fr) * | 1999-06-11 | 2003-04-11 | Solutions | Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance, son procede de preparation et ses applications |
| WO2003024316A2 (en) * | 2001-09-21 | 2003-03-27 | Stryker Corporation | Pore-forming agents for orthopedic cements |
| AU2004272072B2 (en) * | 2003-09-12 | 2010-07-08 | Etex Corporation | Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins |
| FR2861396B1 (fr) | 2003-10-24 | 2005-12-16 | Commissariat Energie Atomique | Derives amphiphiles de cyclodextrines,leur procede de preparation et leurs utilisations |
| US8895540B2 (en) * | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| US20070015701A1 (en) | 2005-06-01 | 2007-01-18 | Samuel Zalipsky | Macromolecular conjugates of bone morphogenetic protein-7 |
| US8691273B2 (en) | 2005-07-21 | 2014-04-08 | Lisopharm Ag | Method for producing hydroxyapatite particles |
| FR2914305B1 (fr) | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | Dextran fonctionnalise par des amino-acides hydrophobes. |
| CN100336825C (zh) * | 2005-12-20 | 2007-09-12 | 山东省医药生物技术研究中心 | 重组人成骨蛋白－1的制剂制备方法 |
| JP2009532552A (ja) | 2006-04-07 | 2009-09-10 | アドシア | 二官能化された多糖類 |
| EP1891984A1 (en) | 2006-08-24 | 2008-02-27 | Graftys | Macroporous and highly resorbable apatitic calcium-phosphate cement |
| FR2919188B1 (fr) * | 2007-07-27 | 2010-02-26 | Proteins & Peptides Man | Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps |
| FR2933306B1 (fr) | 2008-07-07 | 2010-09-10 | Adocia | Composition osteogenique comprenant un complexe facteur de croissance polysaccharide anionique, un sel soluble de cation et une matrice organique |
| CN102065882A (zh) * | 2008-04-14 | 2011-05-18 | 阿道恰公司 | 包含生长因子/两亲性聚合物复合物、阳离子的可溶性盐和有机支持物的成骨组合物 |
| FR2933304A1 (fr) * | 2008-07-07 | 2010-01-08 | Adocia | Composition synergique osteogenique |
| FR2934999B1 (fr) | 2008-08-13 | 2011-07-29 | Adocia | Polysaccharides fonctionnalises par des derives du tryptophane |
| FR2936800B1 (fr) | 2008-10-06 | 2010-12-31 | Adocia | Polysaccharide comportant des groupes fonctionnels carboxyles substitues par un derive d'alcool hydrophobe |
| FR2948573B1 (fr) | 2009-07-31 | 2011-11-18 | Adocia | Nouvelle forme d'administration de complexes de proteines osteogeniques |
-
2009
- 2009-07-31 FR FR0903803A patent/FR2948573B1/fr not_active Expired - Fee Related
- 2009-11-19 SG SG2011037108A patent/SG171388A1/en unknown
- 2009-11-19 EP EP09809027A patent/EP2376063A1/fr not_active Withdrawn
- 2009-11-19 MX MX2011005275A patent/MX2011005275A/es not_active Application Discontinuation
- 2009-11-19 AU AU2009317083A patent/AU2009317083A1/en not_active Abandoned
- 2009-11-19 JP JP2011536920A patent/JP2012509303A/ja not_active Withdrawn
- 2009-11-19 CA CA2744150A patent/CA2744150A1/fr not_active Abandoned
- 2009-11-19 WO PCT/FR2009/001332 patent/WO2010058106A1/fr not_active Ceased
- 2009-11-19 BR BRPI0916110A patent/BRPI0916110A2/pt not_active Application Discontinuation
- 2009-11-19 KR KR1020117014109A patent/KR20110086752A/ko not_active Withdrawn
- 2009-11-19 RU RU2011124917/15A patent/RU2011124917A/ru not_active Application Discontinuation
- 2009-11-19 US US12/591,442 patent/US8546356B2/en not_active Expired - Fee Related
- 2009-11-19 CN CN2009801546015A patent/CN102281868A/zh active Pending
-
2011
- 2011-05-19 IL IL213001A patent/IL213001A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG171388A1 (en) | 2011-07-28 |
| IL213001A0 (en) | 2011-07-31 |
| JP2012509303A (ja) | 2012-04-19 |
| US8546356B2 (en) | 2013-10-01 |
| KR20110086752A (ko) | 2011-07-29 |
| FR2948573B1 (fr) | 2011-11-18 |
| FR2948573A1 (fr) | 2011-02-04 |
| BRPI0916110A2 (pt) | 2015-11-03 |
| EP2376063A1 (fr) | 2011-10-19 |
| WO2010058106A1 (fr) | 2010-05-27 |
| CA2744150A1 (fr) | 2010-05-27 |
| AU2009317083A1 (en) | 2010-05-27 |
| US20100166867A1 (en) | 2010-07-01 |
| CN102281868A (zh) | 2011-12-14 |
| MX2011005275A (es) | 2011-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011124917A (ru) | Новая форма введения остеогенных белковых комплексов | |
| JP2012509303A5 (https=) | ||
| RU2010107203A (ru) | Комплексы между амфифильным полимером и остеогенным белком, принадлежащим к семейству вмр | |
| KR101710432B1 (ko) | 히알루론산의 산화된 유도체, 이의 제조 방법 및 이의 변형 방법 | |
| RU2009115681A (ru) | Декстран, функционализированный гидрофобными аминокислотами | |
| CA2744892C (en) | Method to produce hyaluronic acid functionalized derivatives and formation of hydrogels thereof | |
| JP2010534708A5 (https=) | ||
| RU2011116418A (ru) | Комплекс, образованный полисахаридом и нвр | |
| CA2658587A1 (en) | Drug delivery system based on regioselectively amidated hyaluronic acid | |
| JP2012504697A (ja) | 疎水性アルコール誘導体により置換されたカルボキシル官能基を含有する多糖類 | |
| US20120041167A1 (en) | Poly(glutamic acid)-drug conjugate with an amino acid as a linker | |
| CN104903341B (zh) | 由离散数个糖单元组成的骨架组成的经取代阴离子化合物 | |
| HUP0301817A2 (hu) | Kahalalid-vegyületek, elżállításukra szolgáló eljárás, azokat tartalmazó gyógyászati készítmények és alkalmazásuk | |
| EP3328882A1 (en) | Derivatives of elastin-like polypeptides and uses thereof | |
| US20160220689A1 (en) | Macromolecules of dendrimer-platinum conjugates | |
| JP7076433B2 (ja) | 新規細胞傷害性剤およびそのコンジュゲート | |
| EP3101064A1 (en) | Diamine crosslinking agent, acidic polysaccharide crosslinked body, and medical material | |
| BE1023898B1 (fr) | Composition comprenant du silicium et son procédé de préparation | |
| US8501807B2 (en) | Pentaerythritol derivatives | |
| KR20230174751A (ko) | 아미노산과 카르복실산을 사용한 배합물, 유기염 및 이들을 포함하는 조성물과 그 용도 | |
| JP3772468B2 (ja) | Ｌ−アスコルビン酸−２−リン酸亜鉛塩及びその製造方法 | |
| AR031574A1 (es) | Compuestos de fosfina, metodo para el curtido de pieles y usos de los compuestos | |
| JP7397103B2 (ja) | ヒアルロン酸誘導体組成物、医薬組成物及びヒアルロン酸誘導体－薬物結合体組成物 | |
| CN1589772A (zh) | 化妆品 | |
| RU2382050C1 (ru) | Способ получения модифицированной аскорбиновой кислотой сшитой соли гиалуроновой кислоты и биоактивная композиция на ее основе |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20121120 |